Jiangxi Fushine Pharmaceutical Co Ltd (300497) - Total Liabilities
Based on the latest financial reports, Jiangxi Fushine Pharmaceutical Co Ltd (300497) has total liabilities worth CN¥2.21 Billion CNY (≈ $323.44 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how much of Jiangxi Fushine Pharmaceutical Co Ltd's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Jiangxi Fushine Pharmaceutical Co Ltd - Total Liabilities Trend (2011–2025)
This chart illustrates how Jiangxi Fushine Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 300497 asset base.
Jiangxi Fushine Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Jiangxi Fushine Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Honasa Consumer Limited
NSE:HONASA
|
India | Rs6.24 Billion |
|
Bank First National Corp
NASDAQ:BFC
|
USA | $5.13 Billion |
|
Scatec Solar OL
OL:SCATC
|
Norway | Nkr37.71 Billion |
|
Modern Times Group Mtg AB
ST:MTG-B
|
Sweden | Skr8.67 Billion |
|
Guangzhou Goaland Energy Conservation Tech Co Ltd
SHE:300499
|
China | CN¥985.08 Million |
|
Ningbo Kbe Electrical Technology Co
SHE:300863
|
China | CN¥3.33 Billion |
|
Yusys Technologies Co Ltd Class A
SHE:300674
|
China | CN¥1.69 Billion |
|
Renew Energy Global PLC
NASDAQ:RNW
|
USA | $893.64 Billion |
Liability Composition Analysis (2011–2025)
This chart breaks down Jiangxi Fushine Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 300497 net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.22 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.98 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.49 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jiangxi Fushine Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jiangxi Fushine Pharmaceutical Co Ltd (2011–2025)
The table below shows the annual total liabilities of Jiangxi Fushine Pharmaceutical Co Ltd from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥2.20 Billion ≈ $322.60 Million |
-6.58% |
| 2024-12-31 | CN¥2.36 Billion ≈ $345.33 Million |
+0.50% |
| 2023-12-31 | CN¥2.35 Billion ≈ $343.63 Million |
-0.92% |
| 2022-12-31 | CN¥2.37 Billion ≈ $346.83 Million |
+34.12% |
| 2021-12-31 | CN¥1.77 Billion ≈ $258.59 Million |
+77.09% |
| 2020-12-31 | CN¥997.93 Million ≈ $146.03 Million |
-6.59% |
| 2019-12-31 | CN¥1.07 Billion ≈ $156.33 Million |
+1.76% |
| 2018-12-31 | CN¥1.05 Billion ≈ $153.62 Million |
+27.60% |
| 2017-12-31 | CN¥822.70 Million ≈ $120.39 Million |
+33.95% |
| 2016-12-31 | CN¥614.20 Million ≈ $89.88 Million |
+48.56% |
| 2015-12-31 | CN¥413.44 Million ≈ $60.50 Million |
+18.44% |
| 2014-12-31 | CN¥349.09 Million ≈ $51.08 Million |
+12.05% |
| 2013-12-31 | CN¥311.55 Million ≈ $45.59 Million |
+6.80% |
| 2012-12-31 | CN¥291.70 Million ≈ $42.69 Million |
+25.71% |
| 2011-12-31 | CN¥232.04 Million ≈ $33.96 Million |
-- |
About Jiangxi Fushine Pharmaceutical Co Ltd
Jiangxi Fushine Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of APIs and pharmaceutical intermediates in China and internationally. It offers ß-lactamase inhibitors, carbapenem antibiotics, and antiviral drug intermediates; argatroban injection for the treatment of acute ischemic stroke; and doxycycline hydrochloride dispersi… Read more